573675-25-9

Usage

InChI:InChI=1/C6H2BrN3O2/c7-4-1-6(10(11)12)5(2-8)9-3-4/h1,3H

Upstream product

• 15862-37-0 2,5-dibromo-3-nitro-pyridine 
• 544-92-3 copper(I) cyanide 
• 15862-34-7 5-bromo-3-nitro-2-pyridone 
• 6945-68-2 5-bromo-3-nitro-pyridin-2-ylamine 
• 4367-08-2 copper(II) cyanide 

Downstream Products

• 412035-35-9 5-bromo-3-nitro-pyridine-2-carboxylic acid amide 
• 669066-89-1 3-amino-5-bromopyridine-2-carboxylic acid amide 
• 1065609-78-0 5-bromo-3-(2-bromo-4-fluorophenoxy)picolinonitrile 
• 886373-28-0 5-bromo-3-fluoropyridine-2-carbonitrile 
• 1160936-51-5 C₆H₃BrN₂O 
• 945557-04-0 5-bromo-3-chloro-pyridine-2-carbonitrile 
• 1297538-79-4 3-chloro-5-(1-((2-tritylamino)ethyl)-1H-pyrazol-3-yl)picolinonitrile 
• 870997-85-6 3-amino-5-bromo-pyridine-2-carboxylic acid 
• 1393534-89-8 3-(benzyloxy)-5-bromopicolinic acid 
• 1393534-90-1 benzyl 2-(3-(benzyloxy)-5-bromopicolinamido)acetate 
• 1393534-91-2 benzyl 2-(3-(benzyloxy)-5-(6-methoxynaphthalen-2-yl)picolinamido)acetate 
• 1393534-93-4 benzyl 2-(3-(benzyloxy)-5-(naphthalen-2-yl)picolinamido)acetate 
• 1393534-95-6 benzyl 2-(3-(benzyloxy)-5-(6-hydroxynaphthalen-2-yl)picolinamido)acetate 
• 1393534-88-7 3-(benzyloxy)-5-bromopicolinonitrile 

Relevant academic research and scientific papers

NEW BIARYL AMIDE DERIVATIVES

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 and A are as described herein, compositions including the compounds and methods of using the compounds.

NEW BIARYL AMIDE DERIVATIVES

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 and A are as described herein, compositions including the compounds and methods of using the compounds.

Practical synthesis of a potent bradykinin B1 antagonist via enantioselective hydrogenation of a pyridyl N-acyl enamide

(Chemical Equation Presented) A practical and efficient synthesis of bradykinin B1 antagonist 1 is described. A convergent strategy was utilized which involved synthesis of three fragments: 3, 6, and 7. Cross coupling of fragments 6 and 7 followed by amidation with 3 enabled efficient synthesis of 1 in 19 steps total, a 35% overall yield from commercially available pyridine 10. The key to the success of the synthesis was the development of a fluorodenitration step to install the fluorine in pyridine 7 and a catalytic enantioselective hydrogenation of N-acyl enamide 9 to set the stereochemistry.

Bradykinin B1 antagonists: Biphenyl SAR studies in the cyclopropanecarboxamide series

SAR study of the biphenyl region of cyclopropanecarboxamide derived bradykinin B1 antagonists was examined. Incorporation of a pyridine in place of the proximal phenyl ring and chlorination of the distal phenyl ring proved to be well tolerated

QUINAZOLINE DERIVATIVE

This invention provides a compound or its pharmaceutically-acceptable salt of formula (I) wherein R 1 represents a lower alkyl group et al; R 2 and R 3 are same and different and represents hydrogen atm et al; R 4 represents the substituent of the formula (II) et al; X 1 represents NH, O or S; Y represents N or C; Ar is a divalent substituent derived from aryl et al, by removing two hydrogen atoms therefrom; the ring A represents a 5- or 6-membered heteroaryl group; this compounds has a histamine-H3 receptor antagonistic effect or a histamine-H3 receptor inverse-agonistic effect and is useful for preventive or remedy of metabolic system diseases, circulatory system diseases or nervous system diseases.

l-HYDROXYCYCLOALKANECARBOXAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS

α-Hydroxycycloalkanecarboxamide derivatives of formula (I) or a pharmaceutically acceptable salt thereof, wherein formula (a) is a single or double bond; Rl, R2 and R3 are each independently selected from H, halogen and OH; or Rl and R2 attached to the same carbon atom together represent oxo; R4 is H or methyl; R5 is Cl or F; R6 is selected from -CO2-C1-4alkyl, -O-C1-4alkyl, -O- C1-4haloalkyl, 2-methyltetrazol-5-yl, 5-methyl l,2,4-oxadiazol-3-yl, 3-methyl-1,2,4-oxadiazol-5-yl, 5-halomethyl-l,2,4-oxadiazol-3-yl, 3-halomethyl- l,2,4-oxadiazol-5-yl, tetrazol-5-yl, 5-halomethyl-l,2,3-triazolyl, and 5-methyl-l ,2,3-triazolyl; R7 and R8 are each independently Cl or F; and n is 0 or 1, are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.

ASYMMETRIC HYDROGENATION OF ENAMIDES

The present invention provides a process for the preparation of acyl amines of formula (I), enantiomerically enriched at the carbon atom marked with an *; wherein Y is N or CH; R1 and R2 are independently selected from H, halogen, C

ALPHA-HYDROXY AMIDES AS BRADYKININ ANTAGONISTS OR INVERSE AGONISTS

α-Hydroxy amide derivatives of the general formula (I) are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway. R2a is selected from (1) a group selected from Ra. (2) (CH2)nNRbC(O)Ra. (3)(CH2)nNRbSO2Rd.(4)(CH2)nNRbCO2Ra.(5)(CH2)k-heterocycle optionally substituted with 1 to 3 groups independently selected from halogen.nitro, cyano.ORa.SRa.C1-4 alkyl and C1-3 haloakyl wherein said heterocycle is (a) a 5-membered heteroaromatic ring having a ring heteroatom selected from N.O and S. and optionally having up to 3 additional ring nitrogen atoms wherein said ring is optionally benzo-fused; or(b) a 6-membered heteromatic ring containing from 1 to 3 ring nitrogen atoms and N-oxydes thereof. Wherein said ring is optionally benzo-fused. (6)(CH2)kCO2Ra.and (7)(CH2)C(O)NRbRc. R2b is OH or a group selected from R2a; or R2a and R2b together with the carbon atom to which they are attached form a 3-to 7-membered carbocyclic ring optionally substituted with 1 to 4 groups independently selected from halogen. ORa. C1-4 alkyl and C1-4 haloalkyl;

CAPSAICIN RECEPTOR AGONISTS

Capsaicin receptor agonists are provided. Such compounds are ligands that may be used to modulate VRl activity in vivo or in vitro, and are particularly useful in the treatment of conditions responsive to capsaicin receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.

2-SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS

Certain 2-substituted quinazolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathologi